Literature DB >> 3876343

Binding of 125I-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells.

N A Nicola, D Metcalf.   

Abstract

The binding of granulocyte colony-stimulating factor (G-CSF) to murine bone marrow cells was investigated using a radioiodinated derivative of high specific radioactivity which retained full biological activity. The binding was time- and temperature-dependent, saturable and highly specific. The apparent dissociation constant for the reaction was 60-80 pM at 37 degrees C and 90-110 pM at 4 degrees C, similar to that found for the binding of G-CSF to murine leukemic cells (WEHI-3B D+) and significantly higher than the concentration of G-CSF required to stimulate colony formation in vitro. Autoradiographic analysis confirmed the specificity of binding since granulocytic cells were labeled but lymphocytes, erythroid cells and eosinophils were not. Blast cells and monocytic cells were partially labeled, the latter at low levels. In the neutrophilic granulocyte series, grain counts increased with cell maturity, polymorphs being the most heavily labeled but all cells showed considerable heterogeneity in the degree of labeling. Combination of Scatchard analysis of binding with autoradiographic data indicated that mature granulocytes from murine bone marrow exhibited 50-500 G-CSF receptors per cell.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876343     DOI: 10.1002/jcp.1041240222

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  30 in total

1.  Neonatal sepsis and neutrophil insufficiencies.

Authors:  John Nicholas Melvan; Gregory J Bagby; David A Welsh; Steve Nelson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2010-06       Impact factor: 5.311

Review 2.  Polypeptides controlling hematopoietic cell development and activation. I. In vitro results.

Authors:  F Herrmann; R Mertelsmann
Journal:  Blut       Date:  1989-03

3.  Dual control of LIF expression and LIF receptor function regulate Stat3 activation at the onset of uterine receptivity and embryo implantation.

Authors:  J G Cheng; J R Chen; L Hernandez; W G Alvord; C L Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

5.  Hematopoietic growth factors.

Authors:  C A Sieff
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

Review 6.  A (selective) history of Australian involvement in cytokine biology.

Authors:  Nicos A Nicola
Journal:  Cytokine Growth Factor Rev       Date:  2013-03-30       Impact factor: 7.638

7.  G-CSF-activated STAT3 enhances production of the chemokine MIP-2 in bone marrow neutrophils.

Authors:  Hoainam T Nguyen-Jackson; Haiyan S Li; Huiyuan Zhang; Erika Ohashi; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-09-27       Impact factor: 4.962

8.  Identification of a functional receptor for granulocyte colony-stimulating factor on platelets.

Authors:  K Shimoda; S Okamura; N Harada; S Kondo; T Okamura; Y Niho
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Authors:  Pawel Wiczling; Philip Lowe; Etienne Pigeolet; Frank Lüdicke; Sigrid Balser; Wojciech Krzyzanski
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Recombinant interferon-gamma inhibits the expression of IL-4 receptors on human lymphocytes.

Authors:  K A Byron; G A Varigos; A M Wootton
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.